Product Name :
24-Nor Ursodeoxycholic Acid (CAS 99697-24-2)
Synonym :
(3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid; 3α,7β-Dihydroxy-24-nor-5β-cholan-23-oic Acid; Norursodeoxycholic Acid
Application :
CAS:
99697-24-2
Purity:
Molecular Weight:
378.55
Formula :
C23H38O4
Physical state:
Solid
solubility :
Shipping Condition :
Store at 4° C
Melting point:
120-122° C (dec.)
SMILES:
References:
:Pharmacotherapy of cholestatic liver diseases. | Paumgartner, G. 2010. J Dig Dis. 11: 119-25. PMID: 20579215Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. | Beraza, N., et al. 2011. Gut. 60: 387-96. PMID: 21115542Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF- kappa B-mediated inflammatory response in mice. | Fiorotto, R., et al. 2011. Gastroenterology. 141: 1498-508, 1508.e1-5. PMID: 21712022Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. | Fickert, P., et al. 2013. J Hepatol. 58: 1201-8. PMID: 2336979424-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. | Sombetzki, M., et al. 2015. J Hepatol. 62: 871-8. PMID: 25463533Vector-mediated microRNA-21 silencing ameliorates granulomatous liver fibrosis in Schistosoma japonicum infection.Formula of 2,6-Pyridinedicarboxaldehyde | Sombetzki, M.149771-44-8 Chemscene , et al.PMID:33707060 2015. Hepatology. 61: 1787-9. PMID: 25684616Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. | Trauner, M., et al. 2015. Dig Dis. 33: 433-9. PMID: 26045280Therapy of Primary Sclerosing Cholangitis–Today and Tomorrow. | Halilbasic, E., et al. 2015. Dig Dis. 33 Suppl 2: 149-63. PMID: 26641242Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. | Wanek, T., et al. 2016. J Pharm Sci. 105: 106-12. PMID: 26852845Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. | Steinacher, D., et al. 2017. Dig Dis. 35: 282-287. PMID: 28249257Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. | Lazarević, S., et al. 2019. Pharmacol Res. 146: 104333. PMID: 31254667Evidence for functional selectivity in TUDC- and norUDCA-induced signal transduction via alpha 5 beta 1 integrin towards choleresis. | Bonus, M., et al. 2020. Sci Rep. 10: 5795. PMID: 32242141Monomeric bile acids modulate the ATPase activity of detergent-solubilized ABCB4/MDR3. | Kroll, T., et al. 2021. J Lipid Res. 62: 100087. PMID: 34022183Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. | Marchianò, S., et al. 2022. Biochim Biophys Acta Mol Cell Biol Lipids. 1867: 159218. PMID: 35985473